1-苯基-3-(3-苯基丙基)脲 | 70622-91-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苯基-3-(3-苯基丙基)脲
• 英文名称: 1-phenyl-3-(3-phenylpropyl)urea
• CAS: 70622-91-2
• 化学式: C₁₆H₁₈N₂O
• mdl: MFCD03381888
• 分子量: 254.332
• InChiKey: JIWYHHOEZMXBEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-溴-3-苯基丙烷 在 sodium azide 、 palladium 10% on activated carbon 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 水 、 丙酮 、 甲苯 为溶剂， 60.0 ℃ 、101.33 kPa 条件下， 反应 36.0h， 生成 1-苯基-3-(3-苯基丙基)脲
  参考文献：
  名称：

  胺存在下Pd / C催化叠氮化物的羰基化

  摘要：

  据报道，在胺的存在下，脂肪族和芳香族叠氮化物的Pd / C催化简便，有效地羰基化反应。作为一系列生物药物中广泛存在的片段，在CO气氛下使用易于获得的廉价胺与胺进行叠氮化，可以直接合成官能化的不对称脲，而N 2是唯一的副产物。发现不仅芳基叠氮化物而且苄基和烷基叠氮化物也适用于该方法。该程序的另一个特点是采用了高效的钯木炭催化系统。

  DOI：

  10.1021/acs.orglett.6b00381

文献信息

• An efficient two-step synthesis of mono-, di- and triureas from resin-bound amides
  作者：Adel Nefzi、Nhi A Ong、Richard A Houghten

  DOI：10.1016/s0040-4039(00)00845-5

  日期：2000.7

  An efficient method for the solid-phase synthesis of mono-, di- and triureas from resin-bound monoamines, diamines and triamines is described. The exhaustive reduction of solid support-bound amides generated the requisite amines, which, following treatment with isocyanates and cleavage, provided the corresponding ureas in high purity and good yields.

  描述了一种从树脂结合的单胺，二胺和三胺固相合成单，二和三脲的有效方法。固体载体结合的酰胺的彻底还原产生了必要的胺，这些胺在用异氰酸酯处理并裂解后，以高纯度和高收率提供了相应的脲。
• INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION
  申请人：Hammock D. Bruce

  公开号：US20070117782A1

  公开（公告）日：2007-05-24

  The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

  本发明提供了一些化合物，用于治疗高血压的治疗应用中，抑制环氧水解酶。实施本发明的优选化合物类别具有由式1所示的结构，其中Z为氧或硫，W为碳、磷或硫，X和Y各自独立地为氮、氧或硫，而X还可以是碳，R1-R4中至少有一个是氢，当X为氮时，R2为氢，但当X为硫或氧时，R2不存在，当Y为氮时，R4为氢，但当Y为硫或氧时，R4不存在，而R1和R3各自独立地为C1-C20取代或未取代的烷基、环烷基、芳基、酰基或杂环基。
• Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure
  作者：Manoj Manickam、Hitesh B. Jalani、Thanigaimalai Pillaiyar、Niti Sharma、Pulla Reddy Boggu、Eeda Venkateswararao、You-Jung Lee、Eun-Seok Jeon、Sang-Hun Jung

  DOI：10.1016/j.ejmech.2017.04.005

  日期：2017.7

  A series of flexible urea derivatives have been synthesized and demonstrated as selective cardiac myosin ATPase activator. Among them 1-phenethyl-3-(3-phenylpropyl)urea (1, cardiac myosin ATPase activation at 10) mu M = 51.1%; FS = 18.90; EF = 12.15) and 1-benzyl-3-(3-phenylpropyl)urea (9, cardiac myosin ATPase activation = 53.3%; FS = 30.04; EF = 18.27) showed significant activity in vitro and in vivo. The change of phenyl ring with tetrahydropyran-4-yl moiety viz., 1-(3-phenylpropy1)-3-((tetrahydro-2H-pyran-4-y1) methyl)urea (14, cardiac myosin ATPase activation = 81.4%; FS = 20.50; EF = 13.10), and morpholine moiety viz., 1-(2-morpholinoethyl)-3-(3-phenylpropyl)urea (21, cardiac myosin ATPase activation = 44.0%; FS = 24.79; EF = 15.65), proved to be efficient to activate the cardiac myosin. The potent compounds 1, 9, 14 and 21 were found to be selective for cardiac myosin over skeletal and smooth myosins. Thus, these urea derivatives are potent scaffold to develop as a newer cardiac myosin activator for the treatment of systolic heart failure. (C) 2017 Elsevier Masson SAS. All rights reserved.
• Dimmock; Vashishtha; Stables, Pharmazie, 2000, vol. 55, # 7, p. 490 - 494
  作者：Dimmock、Vashishtha、Stables

  DOI：——

  日期：——
• INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION
  申请人：Kroetz Deanna L.

  公开号：US20110245331A1

  公开（公告）日：2011-10-06

  The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.